High-dose ziprasidone-induced acute dystonia

Department of Psychiatry, Columbia University, New York, New York, United States
Progress in Neuro-Psychopharmacology and Biological Psychiatry (Impact Factor: 4.03). 04/2007; 31(2):546-7. DOI: 10.1016/j.pnpbp.2006.10.005
Source: PubMed

ABSTRACT There are few clinical data describing the relative risks of extrapyramidal symptoms (EPS) at higher doses of ziprasidone (i.e., greater than 160 mg/day) when compared to lower doses. We report on a patient who displayed no EPS with ziprasidone 160 mg/day for several months, but did display marked, acute dystonic reactions on ziprasidone 240 mg/day. The observations from the present case indicate that high-dose, ziprasidone-induced acute dystonia may occur even if no such side effects have been experienced at doses up to and including 160 mg/day.

  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Ziprasidone is a second-generation antipsychotic approved for the treatment of schizophrenia and bipolar disorder. The purpose of this review is to assess the overall safety profile of ziprasidone, including its risk for prolonging the electrocardiogram (ECG) QT interval. AREAS COVERED: This paper is a review of product labeling and English language reports located through PubMed and information available on regulatory agency websites, with a focus on the safety and tolerability of ziprasidone. EXPERT OPINION: Although ziprasidone can prolong the ECG QT interval, this has not resulted in increases in sudden death or cardiac sudden death as noted in a large, simple trial and supported by almost a decade of real-world use in the US. Ziprasidone's principal advantage over some other second-generation antipsychotics has been its overall favorable weight and metabolic profile. Similar to most second-generation antipsychotics, ziprasidone has a lower propensity for extrapyramidal side effects and hyperprolactinemia compared to first-generation antipsychotics.
    Expert Opinion on Drug Safety 02/2011; 10(3):437-48. DOI:10.1517/14740338.2011.560114 · 2.74 Impact Factor
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry 05/2007; 31(4):971-971. DOI:10.1016/j.pnpbp.2007.01.026 · 4.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The hydroformylation activity of various 5- and 6-membered P-heterocycles was investigated in platinum-catalysed hydroformylation of styrene. All of the tested ligands, such as the phosphole-, oxaphosphorine- and phoshinine-based ligands proved to be catalytically active. Especially good aldehyde selectivities were obtained with the chelating diphenylphosphino-tetrahydrophosphinine and diphenylphosphino-hexahydrophosphinine ligands. While the two aldehyde regioisomers were formed close to equimolar amounts with the monodentate ligands, high branched selectivities were observed with the chelating ones. The effect of the 4-substitution of the parent styrene on chemo- and regioselectivity was investigated.
    Journal of Organometallic Chemistry 05/2011; 696(10):2234-2237. DOI:10.1016/j.jorganchem.2010.11.045 · 2.30 Impact Factor